Wells Fargo analyst Yanan Zhu upgraded Voyager Therapeutics (VYGR) to Overweight from Equal Weight with a price target of $14, up from $9. The company’s expanded Novartis (NVS) deal is “highly validating” for Tracer, says the analyst, who sees a high likelihood of success in spinal muscular atrophy given Novartis’ expertise. The firm also likes the odds of Voyager’s Huntington’s disease program due to the company’s novel payloads
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VYGR:
- Voyager (NASDAQ:VYGR) Skyrockets on ~$1.3B Licensing Deal with Novartis
- Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies
- Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program
- Voyager Therapeutics selects development candidate for SOD1 program
- Voyager Therapeutics management to meet with Oppenheimer
